Polyrizon Ltd.·Healthcare
Polyrizon Ltd., a biotech company, engages in the development of medical device hydrogels in the form of nasal sprays in Israel. The company's nasal sprays provide a barrier against viruses and allergens from contacting the nasal epithelial tissue. It develops PL-14, a nasal allergies blocker; PL-15 for COVID-19; and PL-16 for influenza. The company was incorporated in 2005 is headquartered in Ra'anana, Israel.
Healthcare
Biotechnology
2
2024-10-29
-4.55

RAANANA, ISRAEL, April 08, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (NASDAQ: PLRZ) (the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced the closing of its previously announced registered direct offering and concurrent private placement with a single institutional investor. The Company issued Ordinary Shares and pre-funded warrants in a registered direct offering. In a concurrent private placement, the Company also issued to the same investor pre-funded and investor warrants. Aggregate gross proceeds to the Company from both transactions were approximately $3.5 million. The transactions closed on April 8, 2026.

Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements Company Concluded 2025 with Robust Cash Position, Debt-Free Balance Sheet and Significant Pipeline Achievements

Raanana, Israel, March 25, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal protective solutions, today announced that it has filed its Annual Report on Form 20-F for the fiscal year ended December 31, 2025, with the U.S. Securities and Exchange Commission (the "SEC").

The Company signed a non-binding MOU with shareholders of Colugo. Colugo's customer include the Israel Defense Forces, national first responders organizations and commercial companies

Raanana, Israel, March 17, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the signing of an agreement with a leading global preclinical Contract Research Organization (CRO), a recognized expert in biocompatibility and regulatory-compliant testing.

Raanana, Israel, March 10, 2026 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq: PLRZ) (“Polyrizon” or the “Company”), a pre-clinical-stage biotechnology company developing intranasal administrated solutions, today announced the successful production of a Good Manufacturing Practice (GMP) batch of clinical trial material (CTM) for its lead product candidate.